增益疗法(GANX.O)股价在盘后交易中暴跌约18%，至每股1.40美元，缘于公司宣布股票和权证发行计划。这家总部位于马里兰州的企业计划通过发行筹集资金，预计净收益将用于推进其核心候选药物GT-02287的临床及非临床开发，该药物旨在治疗神经退行性疾病，包括GBA1帕金森病。Newbridge Securities担任此次发行的唯一账簿管理人。此前，GANX周二收盘下跌8.6%，报1.70美元，年内累计跌幅达21%。根据招股说明书，截至5月31日，公司流通股约3010万股。所有七位覆盖该股的分析师均持看涨观点，中位目标价为8美元，最新LSEG数据印证此预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.